EC Clinical and Medical Case Reports

A novel and non-invasive diagnostic technique called liquid biopsy has significant potential for detecting and tracking a number of ailments, including cancer, neurological disorders, cardiovascular conditions, and infectious diseases. Unlike conventional biopsy techniques, which necessitate intrusive procedures, liquid biopsy uses bodily fluid analysis-specifically, blood, urine, or saliva-to find biomarkers such as extracellular vesicles (EV), circulating tumour DNA (ctDNA), or microRNA (miRNA). Early identification, treatment response tracking, and minimal residual disease assessment are promising for the future, allowing for more individualised cancer treatment with fewer side effects. Through the identification of neurodegenerative biomarkers, liquid biopsy aids in the early diagnosis of Alzheimer's, Parkinson's, and other neurodegenerative disorders, allowing for earlier management, better treatment outcomes, and prognosis. The risk assessment and treatment choices can be made using liquid biopsy biomarkers for myocardial infarction, atherosclerosis, and heart failure. More efficient treatment strategies have been developed due to pathogen identification and liquid biopsy monitoring of illness progression. Because of its transformative approach, liquid biopsy is a superior substitute for conventional diagnostic techniques. It provides comprehensive and real-time insights into the course of a wide range of diseases, making it an essential tool in healthcare.

 Keywords: Liquid Biopsy; Cancer; Brain; Heart; Infection

1. Baev Vesselin., et al. “Liquid biopsy: current status and future perspectives”. Cancers12 (2023): 3205.
2. Adhit Kanishk K., et al. “Liquid biopsy: an evolving paradigm for non-invasive disease diagnosis and monitoring in medicine”. Cureus12 (2023): e50176.
3. Alix-Panabie res., et al. “Liquid biopsy: from concept to clinical application”. Scientific Reports1 (2023): 21685.
4. Varkey Joyce and Theodore Nicolaides. "Tumor-educated platelets: a review of current and potential applications in solid tumors”. Cureus11 (2021): e19189.
5. van der Pol Ymke., et al. “The landscape of cell-free mitochondrial DNA in liquid biopsy for cancer detection”. Genome Biology1 (2023): 229.
6. Han Dongsheng., et al. “Liquid biopsy for infectious diseases: a focus on microbial cell-free DNA sequencing”. Theranostics12 (2020): 5501-5513.
7. Marrinucci Dena., et al. “Case study of the morphologic variation of circulating tumor cells”. Human Pathology 3 (2007): 514-519.
8. Swaminathan R and Asif N Butt. “Circulating nucleic acids in plasma and serum: recent developments”. Annals of the New York Academy of Sciences 1075 (2006): 1-9.
9. Asare-Werehene Meshach., et al. “The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance”. Oncogene 7 (2020): 1600-1616.
10. Ma Liwei., et al. “Liquid biopsy in cancer current: status, challenges and future prospects”. Signal Transduction and Targeted Therapy1 (2024): 336.
11. Eren Erden., et al. “Neuronal-derived EV biomarkers track cognitive decline in Alzheimer’s disease”. Cells 3 (2022): 436.
12. Achour Brahim., et al. “Liquid biopsy for patient characterization in cardiovascular disease: verification against markers of cytochrome P450 and P-glycoprotein activities”. Clinical Pharmacology and Therapeutics6 (2022): 1268-1277.
13. Burnham P., et al. “Urinary cell-free DNA is a versatile analyte for monitoring infections of the urinary tract”. Nature Communication1 (2018): 2412.
14. Henley S Jane., et al. “Annual report to the nation on the status of cancer, part I: National cancer statistics”. Cancer10 (2020): 2225-2249.
15. Nikanjam Mina., et al. “Liquid biopsy: current technology and clinical applications”. Journal of Hematology and Oncology1 (2022): 131.
16. Adashek Jacob J., et al. “Hyperprogression and immune checkpoint inhibitors: hype or progress?”. The Oncologist2 (2020): 94-98.
17. Khagi Yulian., et al. “Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor-based immunotherapy”. Clinical Cancer Research19 (2017): 5729-5736.
18. Tie Jeanne., et al. “Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer”. Annals of Oncology8 (2015): 1715-1722.
19. Gerlinger Marco., et al. “Intratumor heterogeneity and branched evolution revealed by multiregion sequencing”. New England Journal of Medicine10 (2012): 883-892.
20. Murtaza Muhammed., et al. “Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer”. Nature Communications1 (2015): 8760.
21. Carr T Hedley., et al. “Defining actionable mutations for oncology therapeutic development”. Nature Reviews Cancer5 (2016): 319-329.
22. Kato Shumei., et al. “Therapeutic actionability of circulating cell-free DNA alterations in carcinoma of unknown primary”. JCO Precision Oncology 5 (2021): 1687-1698.
23. Ikeda Sadakatsu., et al. “MEt alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis”. Journal of Hematology and Oncology1 (2018): 76.
24. Jensen Taylor J., et al. “Genome-wide sequencing of cell-free DNA enables detection of copy-number alterations in patients with cancer where tissue biopsy is not feasible”. Molecular Cancer Therapeutics11 (2021): 2274-2279.
25. Goodman Aaron M., et al. “Assessing CAR T-cell therapy response using genome-wide sequencing of cell-free DNA in patients with B-cell lymphomas”. Transplantation and Cellular Therapy1 (2022): 30.e1-30.e7.
26. Mathios Dimitrios., et al. “Detection and characterization of lung cancer using cell-free DNA fragmentomes”. Nature communications1 (2021): 5060.
27. Malhotra Sunny., et al. “Liquid biopsy in neurological diseases”. Cells14 (2023): 1911.
28. Loyfer Netanel., et al. “A DNA methylation atlas of normal human cell types”. Nature7943 (2023): 355-364.
29. Kuang Yaoyun., et al. “Adipose-derived mesenchymal stem cells reduce autophagy in stroke mice by extracellular vesicle transfer of miR-25”. Journal of Extracellular Vesicles1 (2020): e12024.
30. Chen Lei., et al. “5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Diagnostic Biomarkers for Late-Onset alzheimer's Disease”. Journal of Alzheimer's Disease: JAD2 (2022): 573-585.
31. Boyer Emilien., et al. “Comparison of plasma soluble and extracellular vesicles-associated biomarkers in Alzheimer’s disease patients and cognitively normal individuals”. Alzheimer's Research and Therapy1 (2024): 141.
32. Niu Mengyue., et al. “A longitudinal study on α-synuclein in plasma neuronal exosomes as a biomarker for Parkinson’s disease development and progression”. European Journal of Neurology6 (2020): 967-974.
33. Burgos Kasandra., et al. “Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer's and Parkinson's diseases correlate with disease status and features of pathology”. PloS one 5 (2014): e94839.
34. Xie Shishuai., et al. “Differential expression and significance of miRNAs in plasma extracellular vesicles of patients with Parkinson’s disease”. International Journal of Neuroscience7 (2022): 673-688.
35. Pyle Angela., et al. “Reduced cerebrospinal fluid mitochondrial DNA is a biomarker for early-stage Parkinson's disease”. Annals of Neurology6 (2015): 1000-1004.
36. Sjoqvist Sebastian and Kentaro Otake. "A pilot study using proximity extension assay of cerebrospinal fluid and its extracellular vesicles identifies novel amyotrophic lateral sclerosis biomarker candidates”. Biochemical and Biophysical Research Communications 613 (2022): 166-173.
37. Otake Kentaro., et al. "Identification of biomarkers for amyotrophic lateral sclerosis by comprehensive analysis of exosomal mRNAs in human cerebrospinal fluid”. BMC Medical Genomics1 (2019): 7.
38. Mendioroz Maite., et al. “Liquid biopsy: a new source of candidate biomarkers in amyotrophic lateral sclerosis”. Annals of Clinical and Translational Neurology6 (2018): 763-768.
39. Iparraguirre Leire., et al. “Whole-transcriptome analysis in peripheral blood mononuclear cells from patients with lipid-specific oligoclonal IgM band characterization reveals two circular RNAs and two linear RNAs as biomarkers of highly active disease”. Biomedicines12 (2020): 540.
40. Selmaj Igor., et al. “Global exosome transcriptome profiling reveals biomarkers for multiple sclerosis”. Annals of Neurology5 (2017): 703-717.
41. Singh Jaspreet., et al. “Targeted stage-specific inflammatory microRNA profiling in urine during disease progression in experimental autoimmune encephalomyelitis: markers of disease progression and drug response”. Journal of Neuroimmune Pharmacology1 (2016): 84-97.
42. Sharma Smriti., et al. “Nucleic acid liquid biopsies in cardiovascular disease: Cell-free RNA liquid biopsies in cardiovascular disease”. Atherosclerosis 398 (2024): 118584.
43. Zhang Qin., et al. “Circulating mitochondrial DAMPs cause inflammatory responses to injury”. Nature 7285 (2010): 104-107.
44. Wei Ruipeng., et al. “Mitochondrial DNA content is linked to cardiovascular disease patient phenotypes”. Journal of the American Heart Association4 (2021): e018776.
45. Barbalata Teodora., et al. “Mitochondrial DNA together with miR-142-3p in plasma can predict unfavorable outcomes in patients after acute myocardial infarction”. International Journal of Molecular Sciences17 (2022): 9947.
46. Dhondup Yangchen., et al. “Low circulating levels of mitochondrial and high levels failure of nuclear DNA predict mortality in chronic heart”. Journal of Cardiac Failure10 (2016): 823-828.
47. Ueda Keitaro., et al. “Cigarette smoke induces mitochondrial DNA damage and activates cGAS-STING pathway: application to a biomarker for atherosclerosis”. Clinical Science (London, England: 1979)2 (2023): 163-180.
48. Zhang Zhiye., et al. “Mitochondrial DNA-LL-37 complex promotes atherosclerosis by escaping from autophagic recognition”. Immunity 6 (2015): 1137-1147.
49. Brinkmann Volker., et al. “Neutrophil extracellular traps kill bacteria”. Science (New York, N.Y.)5663 (2004): 1532-1535.
50. Mangold Andreas., et al. “Coronary neutrophil extracellular trap burden and deoxyribonuclease activity in ST-elevation acute coronary syndrome are predictors of ST-segment resolution and infarct size”. Circulation Research7 (2015): 1182-1192.
51. Le Huu Thanh., et al. “Using a human colonoid-derived monolayer to study bacteriophage translocation”. Gut Microbes1 (2024): 2331520.
52. Bomsel Morgane and Annette Alfsen. “Entry of viruses through the epithelial barrier: pathogenic trickery”. Nature Reviews. Molecular Cell Biology1 (2003): 57-68.
53. Gotts Jeffrey E and Michael A Matthay. “Sepsis: pathophysiology and clinical management”. BMJ (Clinical Research Edition) 353 (2016): i1585.
54. Grumaz Silke., et al. “Next-generation sequencing diagnostics of bacteremia in septic patients”. Genome Medicine1 (2016): 73.
55. Long Yun., et al. “Diagnosis of sepsis with cell-free DNA by next-generation sequencing technology in ICU patients”. Archives of Medical Research5 (2016): 365-371.
56. Blauwkamp Timothy A., et al. “Analytical and clinical validation of a microbial cell-free DNA sequencing test for infectious disease”. Nature Microbiology4 (2019): 663-674.
57. Drouin Alexandre et al. “Interpretable genotype-to-phenotype classifiers with performance guarantees”. Scientific Reports1 (2019): 4071.
58. Shahid Sara., et al. “Antibiotic resistance genes prediction via whole genome sequence analysis of Stenotrophomonas maltophilia”. Journal of Infection and Public Health2 (2024): 236-244.
59. Qi Elizabeth., et al. “Investigation of liquid biopsy analytes in peripheral blood of individuals after SARS-CoV-2 infection”. EBioMedicine 90 (2023): 104519.
60. Hong David K., et al. “Liquid biopsy for infectious diseases: sequencing of cell-free plasma to detect pathogen DNA in patients with invasive fungal disease”. Diagnostic Microbiology and Infectious Disease3 (2018): 210-213.
61. Lukianenko Nataliia., et al. “Finding a molecular genetic marker for the incidence of recurrent episodes of acute obstructive bronchitis in children”. Journal of Medicine and Life5 (2021): 695-699.
62. Ravichandran Sathyabaarathi., et al. “VB10, a new blood biomarker for differential diagnosis and recovery monitoring of acute viral and bacterial infections”. EBioMedicine 67 (2021): 103352.